Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. - Wikidata - wikimedia - TriplyDB

Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.

Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.

http://www.wikidata.org/entity/Q35483810

about

Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report Preliminary Results on the Feasibility of Using ARFI/SWEI to Assess Cutaneous Sclerotic Diseases.Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission.Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.Nutritional status and hyperglycemia in the peritransplant period: a review of associations with parenteral nutrition and clinical outcomes Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease.Administration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effects Current issues in chronic graft-versus-host disease.Graft-versus-host disease: state of the science.Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease How we treat chronic graft-versus-host disease.National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.Clinical impact of H-Y alloimmunity Treatment of chronic graft-versus-host disease: Past, present and future.Humanized Chronic Graft-versus-Host Disease in NOD-SCID il2rγ-/- (NSG) Mice with G-CSF-Mobilized Peripheral Blood Mononuclear Cells following Cyclophosphamide and Total Body Irradiation.Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.Proteomic analysis of saliva from patients with oral chronic graft-versus-host disease Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.Evaluation of prognostic factors among patients with chronic graft-versus-host disease.Brazilian workshop model to train investigators in chronic graft-versus-host disease clinical trials according to the 2005-2006 National Institutes of Health recommendations.Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type.A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation.Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis.Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease.Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice.Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match.Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders.Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells.Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease.Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma.

P2860

Q24187102-50BC564D-E835-4DA7-9A54-7CC964DBB294 Q24200272-B4336782-5A5B-4752-845F-040E1E42DE1B Q26787230-F44039F6-A6B7-40F6-AFCA-60CAEA2597DE Q26827651-BE6D6697-46E2-4802-879E-B8F625E46B93 Q30371343-3154C0AE-7AF4-4112-BE32-9AF87B8F3FAC Q30408294-A1CE7E0E-6B9C-4E79-A5CB-56766C9A3239 Q33756719-EE7705D5-7513-459F-8D4F-96A273746387 Q33758951-116BA624-AFF9-43BA-AD5F-952B0A7E7FEB Q33809599-B3FBD368-DD7E-4C1D-8355-04335AB30758 Q33905411-07361B95-570D-42E1-A367-6070A77D0003 Q33917187-257C5021-C80B-46AF-B9AE-42EF04A50950 Q33977923-6E43B2E8-EF0A-4D3E-81B9-324EB8329CE1 Q34272547-544C3DB1-8726-40A7-B3B3-DBF77BE855FD Q35004923-0C63E9C6-9B87-44BF-B00D-4A2414287A2F Q35085226-BA6A5441-E196-4B3B-A9A9-831A3C9A646E Q35140097-1756A374-7512-4C76-A170-47509DFFA39C Q35235186-FC07AB10-85FD-4BEF-98F8-A05CA61BD7E9 Q35524687-05278ACF-A802-47D6-8F4C-54A35EB62126 Q35692054-D7E88BAB-FB27-4815-BC82-3010650F8B3D Q35794478-257261C4-DF4B-4912-AC19-531374195AC3 Q35800856-4812555D-67C4-4A6F-BA39-762A663FA048 Q35953410-244EB040-FC38-407F-B64F-FBD25FD6FE01 Q36004178-482D2F8B-7CE7-4254-95FE-20DA21551981 Q36040293-7E68E774-FBEB-4CF4-9A6B-DF331BFCB546 Q36133013-33EB1AF0-0848-4CB8-BC99-D4F8CDEBAA8A Q36153664-2AF4CBC7-2459-487D-AFE1-8F6971589970 Q36252702-2D37ECF8-D233-483B-A05D-771245948B20 Q36530726-29CE7931-0057-48B7-B658-7B122F4EC605 Q36662042-DB7A5ACD-B0A4-4F48-B5CE-E20BFE588D84 Q36709850-7EE09412-273D-43D9-9AE0-7FD9C8DBB3B5 Q36747224-719E84B3-148E-4AB9-A99C-2F0E952CF2CA Q36813127-A1AB6BDF-5EAE-4FC8-AAAC-24189FA1BB9B Q36876981-F01355FC-BE1D-4DB6-843F-16CAACCFBCB8 Q36905580-73F13D8B-1BFB-4616-92FE-F03D24C47C20 Q36928725-A9E00C01-D958-446B-B122-E60ECC4F9F97 Q36940174-82C70CB2-75A9-49F6-972D-6891D5BDB0CB Q37104254-4C0DC93F-38F4-4830-9A9F-ECA9A4D7B803 Q37104281-0ADFFDE9-F908-4599-ACEA-A4E7E3E30FE0 Q37113099-C5BA5192-A812-47B2-8491-9610501DD334 Q37212916-746B6725-ED03-4D30-9FF8-666F822122D2

P2860

Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.

http://www.wikidata.org/entity/Q35483810

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Global and organ-specific chro ...... e 2005 NIH Consensus Criteria.

@ast

Global and organ-specific chro ...... e 2005 NIH Consensus Criteria.

@en

type

label

Global and organ-specific chro ...... e 2005 NIH Consensus Criteria.

@ast

Global and organ-specific chro ...... e 2005 NIH Consensus Criteria.

@en

prefLabel

Global and organ-specific chro ...... e 2005 NIH Consensus Criteria.

@ast

Global and organ-specific chro ...... e 2005 NIH Consensus Criteria.

@en

P1433

Q35483810-B9A3B2A2-0B98-4FC5-9185-07836ED26B7C

P1476

Q35483810-426B4D4E-D9A7-4E8C-BDE8-363DFBCF7FE0

P2093

Q35483810-26129B3A-E8CA-45BC-B842-8E2C71DF54D0

Q35483810-299C1474-A204-48B6-B601-008F22C380B3

Q35483810-3283F761-2CC0-4783-8B46-1F785D9E4143

Q35483810-37AA4CC8-4D27-42FC-A62A-07B5FC715128

Q35483810-76119F7D-B3BE-4C1E-8539-0637A275E85E

Q35483810-926CF11D-50D1-45FB-935A-3A56B3A1638E

Q35483810-986C2315-B1AB-47FE-A2CC-2A5681076698

Q35483810-A8B5E4D4-7042-4162-B76B-886448A662B5

Q35483810-BCE111E9-28AC-4A9B-8CA0-2B0FD6B87662

Q35483810-BD021E5C-BCB4-47D2-95B0-E8DF5F36D589

P2860

Q35483810-191E384A-1321-40B9-9894-F1520FD5E0BA

Q35483810-265BD664-DECB-4447-B261-379F9CA7DA1E

Q35483810-29C40173-F938-4D5D-9BB8-BEBBADFCB476

Q35483810-2A4BBF37-BCAF-4733-B218-61194F45C640

Q35483810-2DA9AD67-BC4D-4B63-A340-CE133877C023

Q35483810-41762C5F-3E72-4AB2-BC6C-68383C886D5A

Q35483810-77B63B40-D77D-4E2A-A79B-8F8711D8EDB2

Q35483810-934E06AA-592B-4C07-B609-880D9E329D8A

Q35483810-94062E2C-9C97-4C70-BF90-90DAD01566B6

Q35483810-9CE8EFBB-E13C-49A1-8081-B3DCA47DEA0E

P304

Q35483810-E104544E-105C-40BC-BC91-A37837C370B0

P31

Q35483810-A1A8B81A-06D0-4F49-9CDF-B56D4963183C

P356

Q35483810-30E24BED-F890-49BA-9A6B-AB2B418E2A02

P407

Q35483810-97BBE93E-313D-4A13-9DEE-ABF14D8BD112

P433

Q35483810-5C9D9B3B-B558-4EFC-BE3E-8A5B39BDA3E3

P478

Q35483810-018EA543-AE81-41B0-8972-3151E6E33CA9

P50

Q35483810-F9F51907-EC23-4EB2-9548-A1D10A5AA3D4

P577

Q35483810-863FB5AA-7921-49C8-976E-CCF2167A8AB4

P5875

Q35483810-0F158B0E-3F2F-4499-95A4-915EF1E293AC

P698

Q35483810-105907A4-5FA6-4AA3-8AC3-7E0EB2FF61FA

P932

Q35483810-8248A416-7244-4882-89CF-C6A52FC2299C

P356

BLOOD-2011-03-344390

P1433

P1476

Global and organ-specific chro ...... e 2005 NIH Consensus Criteria.

@en

P2093

Corey Cutler

http://www.w3.org/2001/XMLSchema#string

Daniel J Weisdorf

http://www.w3.org/2001/XMLSchema#string

David Jacobsohn

http://www.w3.org/2001/XMLSchema#string

Georgia B Vogelsang

http://www.w3.org/2001/XMLSchema#string

Jeanne Palmer

http://www.w3.org/2001/XMLSchema#string

Joseph Pidala

http://www.w3.org/2001/XMLSchema#string

Madan Jagasia

http://www.w3.org/2001/XMLSchema#string

Mary E D Flowers

http://www.w3.org/2001/XMLSchema#string

Mukta Arora

http://www.w3.org/2001/XMLSchema#string

Paul J Martin

http://www.w3.org/2001/XMLSchema#string

P2860

Development of a prognostic model for grading chronic graft-versus-host disease.

Lung function and long-term complications after allogeneic hematopoietic cell transplant.

Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria.

Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report.

Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report.

Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD.

Duration of immunosuppressive treatment for chronic graft-versus-host disease.

Chronic graft-versus-host disease: a prospective cohort study.

P304

4242-4249

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-03-344390

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51523233

http://www.w3.org/2001/XMLSchema#string

P698

21791424

http://www.w3.org/2001/XMLSchema#string

P932

3204740

http://www.w3.org/2001/XMLSchema#string